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PROINFLAMMATORY MEDIATORS DOWNREGULATE
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR
γ1 EXPRESSION AND ACTIVITY IN OSTEOARTHRITIC
SYNOVIAL FIBROBLASTS
N. Chabane, N. Zayed, M. Benderdour, J. Martel-Pelletier,
J-P. Pelletier, H. Fahmi
University of Montreal, Montreal, PQ, Canada
Purpose: Peroxisome proliferator-activated receptor gamma
(PPARγ) is a nuclear receptor involved in the regulation of many
cellular processes including inﬂammation. We and others have
previously shown that PPARγ activators inhibit several inﬂamma-
tory and catabolic responses in synovial ﬁbroblasts in vitro and
are protective in animal models of osteoarthritis. PPARγ has two
isoforms, PPARγ1 and PPARγ2, generated by alternative pro-
moters and differential splicing. So far, little is known about the
factors and the mechanisms that regulate PPARγ1 and PPARγ2
expression in synovial ﬁbroblasts.
Methods: Synovial ﬁbroblasts were treated with increasing con-
centrations of IL-1β, TNF-α, IL-17 or PGE2 for different time
periods. PPARγ1 and γ2 mRNA and protein levels were eval-
uated by real-time PCR and Western blotting analysis, respec-
tively. PPARγ1 promoter activity and transcriptional activity were
analyzed in transient transfection experiments.
Results: Quantiﬁcation of PPARγ1 and PPARγ2 mRNAs re-
vealed that PPARγ1 mRNA levels were 20-fold higher than
PPARγ2 mRNA levels. IL-1β, TNF-α, IL-17 and PGE2 reduced
the expression of PPARγ1 protein in a dose-dependent man-
ner. Similarly, these factors dose- and time-dependently inhibited
the expression of PPARγ1 mRNA as well as PPARγ1 promoter
activity, suggesting that these effects occurred at the transcrip-
tional levels. Finally, we demonstrated that IL-1β, TNF-α, IL-17
and PGE2 dose-dependently suppressed PPARγ1 transcriptional
activity.
Conclusions: These results suggest that OA synovial ﬁbroblasts
predominantly express the PPARγ1 isoform, and that IL-1β, TNF-
α, IL-17 and PGE2 may contribute to the pathogenesis of arthritis
by downregulating the expression and activity of PPARγ1.
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ALL-TRANS RETINOIC ACID IS ANTI-INFLAMMATORY IN
INTERLEUKIN-1-STIMULATED SYNOVIAL FIBROBLASTS
BY RETINOIC ACID RECEPTOR-INDEPENDENT
MECHANISMS
M. Kirchmeyer, M. Koufany, S. Sebillaud, P. Netter,
J-Y. Jouzeau, A. Bianchi
Laboratoire de Physiopathologie et Pharmacologie Articulaires,
Vandoeuvre les Nancy, France
Purpose: Rheumatoid arthritis (RA) is a chronic inﬂammatory
disease characterized by synovitis and overproduction of pro-
inﬂammatory cytokines leading to destruction of cartilage and
bone. Animal models of arthritis have shown that retinoids could
be anti-arthritic by decreasing the production of cytokines like
IL-6, IL-12, or TNFalpha. Our objectives were to compare the
cytokine suppressive potency of various agonists of retinoid
receptors in rat synovial ﬁbroblasts and to explore the signalling
pathways accounting for the modulation of IL-1beta, TNFalpha
and IL-6 by these drugs.
Methods: Rat synovial ﬁbroblasts obtained by sequential enzy-
matic digestion were subcultured until the 4th passage. Cells
were stimulated with 10 ng/ml of IL-1beta, chosen as an inﬂam-
matory cytokine, in the presence or absence of 1 µM of all-trans
retinoic acid (ATRA, RAR [retinoic acid receptor] agonist) or 9-cis
retinoic acid (9-cis RA, RAR/RXR [retinoid X receptor] agonist)
or 0.3 µM of BMS-649 (RXR agonist). IL-1-beta, TNFalpha, and
IL-6 mRNA levels were assessed by RT-quantitative PCR and
corresponding mediator levels by immunoenzymatic-assays in
culture supernatants. The dependence of ATRA effect on pro-
tein neo-synthesis or mRNA stabilization was controlled with
cycloheximide (CHX) or actinomycin D (ACTD) respectively. The
contribution of RAR isotypes to ATRA effect was checked with
selective RAR agonists or siRNAs for each RAR isotype. The
inhibitory potency of ATRA on NF-IL-6, NF-kappaB and AP-1 ac-
tivation was evaluated by gene reporter (luciferase) technology
and on MAPK pathway by western blotting.
Results: The IL-1-stimulated expression of IL-1-beta, TNFalpha
and IL-6 was decreased by more than 70% by ATRA or 9-cis
RA, but not by BMS-649, consistently with a RAR-dependent
inhibitory effect. Inhibition of IL-1-beta and TNFalpha, but not
of IL-6 expression, by ATRA required de novo protein synthe-
sis whereas mRNAs stability wasn’t affected by the drug. The
selective agonists BMS-753 (RAR-alpha), -453 (RAR-beta) or
-961 (RAR-gamma) and RAR siRNAs failed to reproduce or to
antagonize the inhibitory potency of ATRA respectively. Gene
reporter assays demonstrated that IL-1-induced activation of
NF-IL-6, AP-1 or NFkappaB was reduced from 30 to 55% by
ATRA. Western-blots showed that IL-1-induced phosphorylation
of ERK1/2 was also decreased (-30 to -50%) by ATRA.
Conclusions: The present work shows that, in synovial ﬁbrob-
lasts: i) ATRA and 9-cis RA displayed a strong cytokine sup-
pressive effect; ii) ATRA acted in a RAR-independent manner,
although with a variable dependence on de novo protein synthe-
sis; iii) ATRA inhibitory potency was supported by a decreased
activation of transcription factors and of ERK1/2 phosphorylation.
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MOLECULAR INSIGHTS INTO STEROID DISSOCIATION
OF CRX-102, A CLINICALLY ACTIVE ANTI-ARTHRITIC
COMBINATION DRUG CANDIDATE
C.C. Fraser, A. Finelli, Y. Wang, C.T. Keith, G.R. Zimmermann
Combinatorx, Cambridge, MA
Purpose: CRx-102 is a synergistic combination drug candi-
date containing dipyridamole (Dp) and a very low dose of the
glucocorticoid prednisolone (Pd) in a modiﬁed-release oral for-
mulation under investigation for the treatment of osteoarthritis
(OA) and rheumatoid arthritis (RA). CRx-102 was well tolerated
and demonstrated clinical activity in three phase 2a trials for the
treatment of osteoarthritis, rheumatoid arthritis (RA), as well as
an investigative biomarker study. We have previously shown that
side effects associated with high-dose glucocorticoids were not
observed after treatment with CRx-102 in the clinic, in vivo, or in
vitro. To understand how CRx-102 synergistically regulates the
expression of mediators involved in the pathogenesis of arthritis
without potentiating steroid side effects, we studied this com-
bination using cell types relevant to the treatment of OA and
RA.
Methods: Results: CRx-102 and its components were tested
for regulation of pro-inﬂammatory proteins expressed in chon-
drocytes and macrophages. IL-1alpha induced primary human
chondrocytes to express several effecter molecules. Pd dose
response curves at their maximal effect levels showed differ-
ential partial inhibition of MMP-3, IL-6, MCP-1 and GRO-alpha.
Dp had effects different from Pd, causing complete inhibition
(MMP-3, MCP-1), partial inhibition (GRO-alpha) or no inhibition
(IL-6), demonstrating Pd and Dp have distinct molecular effects
in this system. In LPS treated mouse bone marrow derived
macrophages Dp (10 uM) synergized with Pd (0.03 uM) to inhibit
